QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
0.0160
-0.0020 (-11.11%)
Delayed:   11:02AM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.02 - 0.02
52 week 0.01 - 0.90
Open 0.02
Vol / Avg. 7,050.00/210,515.00
Mkt cap 2.63M
P/E     -
Div/yield     -
EPS -0.08
Shares 164.19M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -78950.00% -1991.19%
Operating margin -88983.34% -1990.30%
EBITD margin - -1979.85%
Return on average assets -109.25% -113.38%
Return on average equity -139.52% -140.18%
CDP Score - -

Address

Level 1, 194 Miller Street
NORTH SYDNEY, NSW 2060
Australia
+61-2-94928021 (Phone)
+61-2-89200314 (Fax)

Website links

Description

QRxPharma Limited is a commercial-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management. The Company�s complementary pain management product formulations- in both early and late stage clinical development, which include: MOXDUO IR, an immediate release oral capsule for acute pain; MOXDUO CR, a controlled release oral tablet chronic pain; and MOXDUO IV, an intravenous formulation for moderate to severe hospital-based pain. The Company is developing Dual Opioid formulation for treating patients with moderate to server acute or chronic pain. The Company�s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

Officers and directors

Edward M. Rudnic Ph.D. Chief Executive Officer
Chris J Campbell Chief Financial Officer, Company Secretary
Age: 48
M. Janette Dixon Vice President - Global Business Development